Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

23-03-2020 | Uitgave 8/2020

Quality of Life Research 8/2020

Psychotropic polypharmacy and its association with health-related quality of life among cancer survivors in the USA: a population-level analysis

Tijdschrift:
Quality of Life Research > Uitgave 8/2020
Auteurs:
Ami Vyas, Ghadah Alghaith, Meghan Hufstader-Gabriel
Belangrijke opmerkingen

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s11136-020-02478-6) contains supplementary material, which is available to authorized users.
This project was presented as a poster at the International Society for Pharmacoeconomics and Outcomes Research 24th Annual International Meeting, New Orleans, LA, 2019.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose

Cancer survivors that use multiple psychotropic medications are at an increased risk of psychotropic polypharmacy. We examined the association between psychotropic polypharmacy and health-related quality of life (HRQoL) among cancer survivors living in the USA.

Methods

We used the Medical Expenditure Panel Survey (MEPS) data for 2010, 2012, and 2014 to identify adult cancer survivors. Psychotropic polypharmacy was defined as use of at least two classes of psychotropic prescription medications. The physical component summary (PCS) and the mental component summary (MCS) were obtained from the 12-item Short Form Health Survey version 2 to measure HRQoL. Adjusted ordinary least square regressions were performed to evaluate the association between psychotropic polypharmacy and HRQoL.

Results

Among 31 million US cancer survivors (weighted from a sample of 2609), 16.3% reported psychotropic polypharmacy. Lung cancer survivors had the highest prevalence of psychotropic polypharmacy (22.5%), followed by survivors of breast cancer (17.8%), colorectal, and other gastrointestinal cancers (16.0%). The unadjusted PCS and MCS scores for those with psychotropic polypharmacy were significantly lower than those without psychotropic polypharmacy, overall, and for each cancer type. In multivariable regressions, cancer survivors with psychotropic polypharmacy had significantly lower PCS scores (β =  − 3.63, p < 0.0001) and MCS scores (β =  − 2.28, p = 0.0138) compared to those without psychotropic polypharmacy.

Conclusion

Cancer survivors requiring multiple psychotropic medications have poorer quality of life.

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Extra materiaal
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
Over dit artikel

Andere artikelen Uitgave 8/2020

Quality of Life Research 8/2020 Naar de uitgave